{"ticker": {"uuid": "896301e5-b0f4-4abb-a4ad-b6d9249cee70", "symbol": "ERAS", "name": "Erasca Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSVNCYk85MmFqODVZTFBxQ242OGJVX2VPTXptSEZ0SFBjQktjOFhmeFlCQ3RHMGFWV1pUN3VGa01yVDFDdFJoV2I0dzRCZzU2c3hJRnNhNWkxN21uYnpsX09ZN2o4dmhtcWN1LVgzUUViZENIUnFNOV9aSEpiNmYxMlVWX1FVX1NvQmFUMkZYaVg5TUZIem9GSFpGZTZ4RElq?oc=5", "source_name": "Market source", "published_at": "2026-07-16T03:24:00+00:00", "published_display": "16 Jul 2026 03:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxPOHFIakhUVWt6Wl9WYUVhMDk2MnFIS0xnbUdIWXE2aEZYOEVob3ZzeVAweVVXYjRsWG1vRmlGYS16bzJQNkFSczZibW5uVU1WOTN0UUtSb19EbGthaTZFVHlUYU1SVUZ5TkdnR0JoSm9zNUtOTG9BRHJDRnBYWjdjQUtQR1BJcmV5dmlhcTkxM0tZaURqQjZHNDkxUzM5SzNCdjF1Um10MS1DaWxwN05iNWpnSHVsdHJkczVmWGU2cFdaQ2RPM013bVBEWkRrei1ZSUhiRm9aY05nVWEyN084cUlScEpPbUNtNmlKZ2F2WGptaDNpUnk1SDVFOUhvZmlpSjM0bmNJb0NiMzUtS2daNnMtdG5JZHdfLXBCck9ScTYyTnVNaHlVcFkxSDhRSzdzU0tmdzVHWm5GNkZoSm1SYnZB?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-16T00:00:00+00:00", "published_display": "16 Jul 2026 00:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Closes $632.5 Million Upsized Common Stock Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQNWVaUjdfc3Fjak5pZ0YzOXczVFhPQ3VfWVZST3pyVW1SZVUyV2JIaDBOdlliNzM0T1dwdTNCQ0IxLWdVbm9qVG1iSGhFQm1JOHF3V2pOZnBQTzZrRERKVVNvQ0Z1RmdYRl9scW1uNDU3bjhmZkVvYUthaHNuLVpsUzhVRkk4Q2Y1UHFQRk52aFRMRVhjemd0ZHpfTHNzZzNZWGFERFRhV2Zyam51RldZ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:29:17+00:00", "published_display": "15 Jul 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Erasca (ERAS) and Tenet Healthcare (THC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPcWdvLW1sT1B1cE9HQXpYOWUtZ3BUdFVNWW5aQm9lNGk2cHZSV2dLNzNQZmV4bnBObDZYR0UyTVV2OUNGQlNQeTJySXBlbnZ1Um5jMGp4TkJLZnhZZW81QXl1SmVJVDZoWkVfMjZXRWRzWlhpaU5aQ2w1ZmdKUnoxNkNXWGtMVnI0Wjk3SXlPTFFyVGloenlhdC12Vng2Ri12RUNsWGRfSS00R0RVTktNck1vTndqeE95ZFBuaUlJc0REcTkyR0Zndm55cGtFdUh6MUJObDhhUW9MLWowMS1IbmtERXJPaHpSbDlWV2RSRW9mYkozOGRfbQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-15T20:18:59+00:00", "published_display": "15 Jul 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-announces-closing-upsized-public-200100924.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:01:00+00:00", "published_display": "15 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca intends to use offering proceeds for oncology drug research", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOTFNZM3hXcTdKdkYxSGhvbUdRbUU3R0RfQ3RQbXFEbS1seWthUHJNRVM4SGlwblJVWVRxVXdUaUpjWGNhejJRX2cxZDNhZU1LVzA4OXZhbm52TUdjQTV2cGVOZm1WLTMwZmNIWF9NS0lvQ3l6MlY1cDZuUmRzdFNVdTJmU1hmNzA2cndPTmV2RG05YUJzT2tFWUlxcVRLalpTVWRlRGw5Sy1jWUpaYmROS1ZmSVBNWlVMWWNFSmpHaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:01:00+00:00", "published_display": "15 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca closes $632.5 million public stock offering", "summary": "Erasca Inc. (NASDAQ:ERAS), a precision oncology company, announced the closure of its public offering, raising approximately $632.5 million from the sale of over 36 million common shares at $17.50 each. The proceeds will fund research and development for its product candidates an", "url": "https://www.investing.com/news/company-news/erasca-closes-6325-million-public-stock-offering-93CH-4794147", "source_name": "Investing.com", "published_at": "2026-07-15T20:40:09", "published_display": "15 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "Erasca has announced the closing of its upsized public offering of 33,350,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $100.1 million before deduc", "url": "https://www.moomoo.com/news/post/73028785/press-release-erasca-announces-closing-of-upsized-public-offering-of", "source_name": "Moomoo", "published_at": "2026-07-15T19:40:09", "published_display": "15 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNNjRDQVRQSjNQNHVJb3lWTjlPeGoyeUZ4b3JzZjlVaG9GYjQ4UXE1eEJNdEprRHFsRml1X3QtSnFVUEM4R1NDcGZpUkFKODJHdHlSRkZ2SHRoY0NELUw3aU5nd1I0OVhjUi1zRXRWOEo0TTIyMjFRUDgyZEJsOFdFMUZBTWc0WHpUSkRnYnJTLUgxWUM1?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:13:39+00:00", "published_display": "15 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/erasca-eras-6-2-advancing-141017080.html", "source_name": "Simply Wall St.", "published_at": "2026-07-15T14:10:17+00:00", "published_display": "15 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxOdUhUWXpCdTlvTDZrdktRRVVMaUVpaFZuSXNkTkZ5SWRXNHd6OFFKckZSYUpvMTlxb1RZUGNPbm80aGlOQ19ub0FFXzRPYnVlOTFTaUR6bHVhbUZxTlI0azkwSXdBQlk2OWllc1BjU3FwZnJqczRPZkwwa1J5T19zYnQ4MTRlUUFvZThhNllJQ0RiYW52UzdyR3I1NmF0Tm0tZmxNSTF5OUJEVG5WbGxkRUR3dHdoRE5SUUlmS0gyOTVkako4b3pYRHRwLWRnX0xucnc5MlhQSEowb1lfMmI3ZHgwMjBvV3BoNzVMZUViRTdKRGl2LU9qU1M1M1oyaTU2RHlR?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-15T14:07:00+00:00", "published_display": "15 Jul 2026 14:07", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T09:02:37+00:00", "published_display": "15 Jul 2026 09:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Stock 12\u2011Month Price Target Raised to $21.09, Implies 18% Upside", "summary": "Analysts have raised the 12-month average price target for Erasca, Inc. (ERAS) stock to $21.45, up from $21.27, suggesting a 20% potential upside from its July 13 closing price. The consensus rating among 11 analysts remains \"Buy,\" with 9 analysts recommending a Buy and 2 recomme", "url": "https://www.tradingview.com/news/tradingview:230e96ff1f765:0-erasca-inc-stock-12-month-price-target-raised-to-21-09-implies-18-upside/", "source_name": "TradingView", "published_at": "2026-07-15T04:40:09", "published_display": "15 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit", "summary": "Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Erasca, Inc. (ERAS) for investors who suffered losses. The lawsuit alleges that Erasca failed to disclose that its preclinical data for ERAS-0015 was based on improper comparisons and ", "url": "https://www.morningstar.com/news/pr-newswire/20260714la03805/erasca-inc-eras-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit", "source_name": "Morningstar", "published_at": "2026-07-15T04:40:09", "published_display": "15 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Erasca Inc For: 14 July By Investing.com", "summary": "This article announces the filing of Form 424B5 by Erasca Inc. on July 14, as reported by Investing.com. It is a brief, straightforward notification of a regulatory filing, providing no further details within the article text itself beyond the company name and date of the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-424b5-erasca-inc-for-14-july-93CH-4733976", "source_name": "Investing.com Canada", "published_at": "2026-07-15T04:15:35", "published_display": "15 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock sale", "summary": "Erasca Inc. (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, aiming to raise approximately $550.0 million in gross proceeds. The company plans to use the net proceeds, along with existing cash, to fund research and", "url": "https://www.stocktitan.net/sec-filings/ERAS/8-k-erasca-inc-reports-material-event-74cb25cf1a57.html", "source_name": "Stock Titan", "published_at": "2026-07-15T04:15:35", "published_display": "15 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Notice of August 10, 2026 Application Deadline", "summary": "Kahn Swick & Foti, LLC (KSF) has notified investors of Erasca, Inc. (NasdaqGS: ERAS) about a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product, specifically concerning improp", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327432/6713/en/Erasca-Inc-Notice-of-August-10-2026-Application-Deadline-for-Class-Action-Lawsuit-Contact-Lewis-Kahn-Esq-at-Kahn-Swick-Foti-LLC-Before-Application-Deadline.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T02:15:35", "published_display": "15 Jul 2026 02:15", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results", "summary": "Erasca (ERAS) shares surged 8.9% following encouraging Phase 1 clinical trial results for its cancer treatment candidate, ERAS-0015, which showed significant tumor shrinkage in pancreatic cancer patients. Investment firm Jefferies raised its price target for Erasca to $24 and rei", "url": "https://sg.finance.yahoo.com/news/erasca-eras-surges-8-9-234045926.html", "source_name": "Market source", "published_at": "2026-07-15T01:15:35", "published_display": "15 Jul 2026 01:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Erasca (ERAS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1URDRaa2pMb3VVNnpWWVFGMHl5Q1JtODF5bzN4eHd6RWFVZWJFNGQ5aGc1Z1NGellYSEw0bERYU3B5ckFrRndGcDhxa3VLZ1Z5ZF9KaUQxZVh4bEVRay03TGxHTk9MUVhYU1hBMks2MjZ6NUVtdV9aT0l6M28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T18:36:00+00:00", "published_display": "14 Jul 2026 18:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Erasca Stock Trading Higher Today? - Erasca (NASDAQ:ERAS)", "summary": "Erasca shares are trading higher today after the company unveiled updated preclinical data for its cancer candidate ERAS-0015, showing encouraging early activity. The company also priced an upsized public offering generating approximately $550 million to fund its pipeline and ope", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60454003/erasca-unveils-updated-cancer-candidate-progress-maps-path-toward-pivotal-cancer-trials", "source_name": "Benzinga", "published_at": "2026-07-14T18:15:35", "published_display": "14 Jul 2026 18:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS", "summary": "The Gross Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about a pending class action lawsuit with a lead plaintiff deadline of August 10, 2026. The lawsuit alleges that Erasca issued false and misleading statements regarding its ERAS-0015 drug, specifically conce", "url": "https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-erasca-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-10-2026---eras-302824963.html", "source_name": "PR Newswire", "published_at": "2026-07-14T14:10:54", "published_display": "14 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca investors face August 10 deadline in $11.59 per share securities fraud suit", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVEo3UkFJcVhINjEwRmVRc1ZwSmVYTVVoR2JFYkpCQV9VblZDallDOWk2ZzA5T0VST1VXZ2tEQnZTUWpNNDl4YlBKSGZrZ3ZndWpXX1FhNklwbFFQcTVHRlQ5VjVpa3g2UXBra05XWlUzYXZPejhqX29jVE56c2xZNl9GNEd5QkZVTy1CVEEtQVVCVW5kNnZSVVBubzl4cjh6QnlaWkVva090bFpsR3RoSA?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-14T12:27:28+00:00", "published_display": "14 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Prices Upsized Public Offering of $550 Million", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-prices-upsized-public-offering-082932571.html", "source_name": "MT Newswires", "published_at": "2026-07-14T08:29:32+00:00", "published_display": "14 Jul 2026 08:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Offering All Shares to Be Sold >ERAS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLTNkWUFGVDExR0gxNGRXcU9IenluelB4OXhqR2NjTEtxTnk1VWxXTEFIQl92a0xLR3FvUlhBZXVxa1hHYWNOc1ZNR1lFOG1JSG5MdjNwVlg4THBaZUEzbkJfZFFPMTNNTWM3ZDBXTjVfVWotZ1NJVy1Gdl9PVE1ZQmpfb0NWOFhsRVpaMEhGSDl6a05TQ1J6NHFtWnVkVlI3aEV4akVKNy15UlpyY2ZkY0xzZkdRemZRYTZN?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T03:50:25+00:00", "published_display": "14 Jul 2026 03:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Erasca Announces Pricing of Upsized Public Offering of Common Stock", "summary": "Erasca has announced the pricing of an upsized public offering of its common stock. The offering is expected to generate significant interest from investors. This move could provide Erasca with additional capital to fund its operations and strategic initiatives.", "url": "https://www.moomoo.com/news/post/72896465/press-release-erasca-announces-pricing-of-upsized-public-offering-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T04:15:35", "published_display": "14 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Pricing of Upsized Public Offering of Common Stock", "summary": "Erasca, Inc. (Nasdaq: ERAS) has announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, expecting gross proceeds of approximately $550.0 million. The clinical-stage oncology company plans to use these proceeds, along with ", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/erasca-announces-pricing-of-upsized-public-offering-of-common-stock/2383768", "source_name": "The Manila Times", "published_at": "2026-07-14T03:28:27", "published_display": "14 Jul 2026 03:28", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Plans to Use $550M Offering Proceeds for Drug Development", "summary": "Erasca (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share, expecting to raise approximately $550 million in gross proceeds. The company plans to use these funds, alongside existing cash, to finance research and developmen", "url": "https://www.stocktitan.net/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-dgwsm22haxu4.html", "source_name": "Stock Titan", "published_at": "2026-07-14T03:12:27", "published_display": "14 Jul 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (NASDAQ: ERAS) targets $500M stock sale to fund pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWTM5Rm5Hc3VPaFhYRkk2eTlWdzFJTXlkeEF0S0c2ck5YZV9jZEVGeXZubmFTNldJQU1saGNJaG4zTVZMRWVNNmt5QUtLTUNia3h1ZEN3RHA5ZkZna2FjMGlfdmt6RkhVMG5QdW1qSXZ5ekFyWjBrcGFTd3RkWG9YUGNiQ29idGVCV3paU092WDVGTVUxd1JvMEpsUUpqYVlPN3dZX3dnZ01yNmNNaWV5OUE2Q1BjVE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T21:24:10+00:00", "published_display": "13 Jul 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Plans $500 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-plans-500-million-underwritten-211745953.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:17:45+00:00", "published_display": "13 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Proposed $500 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbHFsNEE1T1RvRjc2cWowcmQ0UkhGcDhZM1BPd2wyQWp5dlNRNlhZamhkemtsTUNVbEhhaDNsT2FWdW1GS3J6aV9YQnBsREVEbXZ6Z3dqdE9fdi16OEsxUzU5VEg3Y09yRmlaU0h2Q2lBb2J5eGFGY05lcUtDSFhGTU5Ea3RpcmVSYUsySWRwVDd6aC1ldGMwWWlONkxOUWp2V1VIaFBZTlc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T20:30:00+00:00", "published_display": "13 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Proposed Public Offering of $500 Million of Common Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-announces-proposed-public-offering-201900047.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T20:19:00+00:00", "published_display": "13 Jul 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug developer Erasca plans $500M stock sale, plus $75M option", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQeXhheXpiNkFlaVAzVW5MMUFtTUIxWEdfcHN3YVRsQks3cjNDeVYxd3dPUzl2RXpWYVZuX2d1djRnUVI4ZnMxdUEyRDNwMHMzZDdFZE9ZTFNmMWI5ZGlyR1Y0NkpMeXZhZmF5YkRkelpRcTdkbGhhRzV6SUNqVzFBNGpfd044Umt4YlVfdzVZaE5RaS1uYzVmTmdRM2QwdXAzQWN1MHZWRFVNUllOem04TE5qWHhFTF93VnlxdnlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:19:00+00:00", "published_display": "13 Jul 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca reports phase 1 data for RAS inhibitor ERAS-0015", "summary": "Erasca Inc. announced updated preliminary Phase 1 data for its investigational oral pan-RAS molecular glue, ERAS-0015, showing a 57% unconfirmed overall response rate in patients with RAS-mutant solid tumors, specifically KRAS G12X pancreatic ductal adenocarcinoma. The company pl", "url": "https://www.investing.com/news/company-news/erasca-reports-phase-1-data-for-ras-inhibitor-eras0015-93CH-4789151", "source_name": "Investing.com", "published_at": "2026-07-13T21:12:27", "published_display": "13 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (NASDAQ: ERAS) sets up shelf to issue stock, debt and warrants", "summary": "Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, has filed an automatic shelf registration as a well-known seasoned issuer. This registration allows Erasca to offer various securities, including common stock, preferred stock, debt securities, and warrants", "url": "https://www.stocktitan.net/sec-filings/ERAS/s-3asr-erasca-inc-sec-filing-9f093d2d13ba.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:27", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit", "summary": "The Rosen Law Firm reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, of the August 10, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges Erasca and its executives made false and misleading ", "url": "https://www.keybiscayneportal.com/online_features/press_releases/eras-investors-have-opportunity-to-lead-erasca-inc-securities-fraud-lawsuit/article_bb42ef90-2f28-584d-a3e2-7332404979b3.html", "source_name": "Key Biscayne Portal", "published_at": "2026-07-13T16:10:55", "published_display": "13 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS", "summary": "Levi & Korsinsky, LLP is encouraging investors in Erasca, Inc. (NASDAQ: ERAS) who suffered losses to contact their firm regarding a pending class action lawsuit. Investors who purchased ERAS securities between January 14, 2025, and April 26, 2026, may be eligible to recover damag", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326285/3080/en/Levi-Korsinsky-Reminds-Erasca-Inc-Investors-of-the-Pending-Class-Action-Lawsuit-With-a-Lead-Plaintiff-Deadline-of-August-10-2026-ERAS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T13:41:24", "published_display": "13 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Goldman Sachs initiates Erasca stock coverage as early-stage biotech By Investing.com", "summary": "Goldman Sachs has initiated coverage on Erasca Inc. (NASDAQ: ERAS) with an Early-Stage Biotech rating. Despite a significant surge in stock price over the past year, InvestingPro data suggests the company is overvalued. Erasca focuses on precision oncology, developing treatments ", "url": "https://m.in.investing.com/news/stock-market-news/goldman-sachs-initiates-erasca-stock-coverage-as-earlystage-biotech-93CH-5492649?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-13T09:41:24", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc.", "summary": "The Rosen Law Firm is encouraging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to secure legal counsel before the August 10, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges ", "url": "https://www.globenewswire.com/news-release/2026/07/12/3325869/673/en/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-Erasca-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ERAS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-12T21:40:03", "published_display": "12 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) and its officers. The lawsuit seeks to recover damages for investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, alleging that the compa", "url": "https://natlawreview.com/press-releases/eras-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-erasca-9", "source_name": "The National Law Review", "published_at": "2026-07-12T12:11:04", "published_display": "12 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026", "summary": "Faruqi & Faruqi, LLP has reminded Erasca (NASDAQ: ERAS) investors of the upcoming August 10, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Erasca made false or misleading statements regarding its ERAS-0015 drug", "url": "https://natlawreview.com/press-releases/eras-shareholder-notice-faruqi-faruqi-llp-reminds-erasca-eras-investors", "source_name": "The National Law Review", "published_at": "2026-07-11T17:10:28", "published_display": "11 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS", "summary": "ClaimsFiler is reminding investors of Erasca, Inc. (NasdaqGS: ERAS) who suffered losses exceeding $100,000 to file lead plaintiff applications by August 10, 2026. This securities class action lawsuit alleges that Erasca and its executives made false and misleading statements rega", "url": "https://www.prnewswire.com/news-releases/erasca-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-erasca---eras-302823057.html", "source_name": "PR Newswire", "published_at": "2026-07-11T02:00:23", "published_display": "11 Jul 2026 02:00", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.", "summary": "Robbins LLP is reminding stockholders about a class action lawsuit filed against Erasca, Inc. (NASDAQ: ERAS) for alleged non-disclosure of patent and trade secret infringement risks related to its drug candidate ERAS-0015. The lawsuit covers investors who purchased securities bet", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325728/0/en/robbins-llp-urges-eras-stockholders-to-contact-the-firm-for-information-about-the-class-action-against-erasca-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T19:09:05", "published_display": "10 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Erasca\u2019s Shift Into Russell Growth Indexes (ERAS) Quietly Redefine Its Biotech Investment Story?", "summary": "In June 2026, Erasca, Inc. transitioned from Russell value and microcap benchmarks to Russell growth indexes, including the Russell 2000 and 3000 Growth series. This reclassification reshapes how institutions categorize the biotech company, which currently has no revenue, signifi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/does-erascas-shift-into-russell-growth-indexes-eras-quietly/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T17:40:22", "published_display": "10 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall ...", "summary": "The Schall Law Firm has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, covering investors who purchased shares between January 14, 2025, and April 26, 2026. The lawsuit claims Erasca made false and misleading statements regardin", "url": "https://www.caledonianrecord.com/eras-investors-have-opportunity-to-lead-erasca-inc-securities-fraud-lawsuit-with-the-schall/article_4e4b75f7-134e-564a-9aad-b46cab2ff31d.html", "source_name": "Caledonian Record", "published_at": "2026-07-10T15:09:05", "published_display": "10 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a shareholder alert for Erasca, Inc. (NASDAQ: ERAS) investors who purchased shares between January 14, 2025, and April 26, 2026. This alert concerns a securities class action lawsuit alleging that Erasca made materially false and/or misleading statem", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325528/0/en/eras-shareholder-alert-erasca-inc-securities-class-action-lawsuit-investors-should-contact-the-gross-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T12:40:15", "published_display": "10 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca (ERAS) Pricey On Its Lawsuit And ERAS 0015 Risks?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T18:42:48+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxORXhtQWFXZ3dNRnNKRnRJUVRIZG84VWxxSHE5VG9qNjBmVUZsS0lBYS0yT0JERHdlcU9rZXR1STJJUkhqMFNCQ0xVWUxmdWMtcEtEcEJTdGloN1NOMFFfRWJST2tqTnRuUEZjQjdXS0RHY1ZzYTVXNjRmMktvMDlFdjUtM05vY1lmVVFPMXpFTW1JTXRDdm1fdjNpMmdiM3I1azlDSUNaX3FpZHZZUV9WOWpWRm5OZTZGVlM5TlhPZmlaZ2ZIRFlURXB5bWxvYlcwTU9FLUN5ZlZOZ2ROTXZ5dVRWT2dPTWFSb2JTMjJNWlpzcVhnQVEzanFLclRPTmNiR3NENll5MlQxbHdkazlhdHFHOVdJOFpmeWJGMGtoaGhlZlNkQUN4VFI2ekVBNDkwUjNMNnBqY2g2X2xFWHQybXhrWHl6YUpFTXM3elYtN0V6Z1pJaVNZZTVmbjhUblE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-02T21:48:00+00:00", "published_display": "02 Jul 2026 21:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca\u2019s (ERAS) Shift Into Russell Growth Indexes Reframing Its Core Investment Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPRHJVa2ZqYlkxZVA2dFJpakVkYUdMQllOVkV3NXlVSGJKTXdJd1hoMEdWR3hLZlhveUx2REpieW50Zjk4M1NBajFwX0hCLUYxdVFjc3FFQ1RHbERmalRPdERFaWt5a09oOFpJd0oyQ2xESlgyU1pobUtIRFc5a3VxV212ZWl5cjlfQVo2ZXgxU3BnUi1RYUpTVnVleU4xTG1lOHJ4S2ZyOEFfeDJoWjlIdWZKVmtXUFloMURjVXY0ajh1bzJVU3hIaDNmVDAySENLX0xiamZn0gHbAUFVX3lxTFBFdDJCNkV3VXJraFNBRHBtN2hXdkxyeVlFSGs2ay1GV0x6Uk42WnhnZUt0M0tqOHZtYnQwYm9WejlPaWU5b1U5d3FCaWh4Rk80YTRLS2tGN0ptQlF5OW92Wk5BaVlzMjFvd2U0bG1fQmgwc1RDYzYtaFdhVG9vOGZpT3M1WkxUcnFGd2QyendsTVFyMWhOd1FrMzJjVHdGRnF4LVFpUGp5RVdSUl9WOVdINHZkU3hxVjdEYUp0Z2RHZlJ5ZVk1MmNwVWNJZkZlckdJald6UGFST09tTQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (NASDAQ: ERAS) investors back board slate and KPMG auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMTlRZi11RU5IcE9tbUpXdWhLSTZVcnc1bTVJei14Mi00Y0RVdWdTWU5LZ1lkUHRPenY3cU53dXJPSFBCdHVHQlh6NWoxUy1DaFBuY09RUnAzYU9UTDA0M0ZoYjZ3R1NPdDJIXzRSeVJ2UFpHRU9Pd3EwaW11OEtSZU9qTUtNYUVvRUo0aWZSSkt6bHVEVWV1LWl1SUdvSVhk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOekNzaHYta3lvQ2ZJT0tVcDBXXzNqTmJoNnVWVHlKdEZZSm5Tdlk3RFhnaHM0MkRiZThNMDBnSkU0bG5QSWRSNUJjUFNUMzlyLVdiWWlIQ25WOFppUnhXQ2JKLWZjel8xc05Kd3RwcjJnMlZFUjh0dWRodmR5Q0ZkMklrRkx1dTRHbk44YXQ2UFhtTzA?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (NASDAQ: ERAS) foundation reports three 8,333\u2011share sales in Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOVU40OUg0c0huNy1OZ0ZmTTRITXJnOWFNbmFmSjdncExHZTV1a0dhS0xEZ1U1aUY2U2RCYmxYUm1wZjJOVjM0MllhdHFMNldzYkp5LVkwM3pva0VfcktjUEx4LXJ0VDJ0SzdvZ29FSG5pdjRwcmxEbXpEcmh5S3YzeTZ0MVdheDdtZGxXdmR1Rkc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Funds, Roderick Wong report 5.2% stake in Erasca (ERAS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ2Y0YTVxMTd4ZWRZM09Oc0x6cmxzcWJXcGRKRnZPM3hUak1vOXA0NVA3by1kZFExb2lldy12aXZTdmwyRzVldFM3VXdaRnk5YUFvUVhuTXk3RGhVbTRFZEdqYWhxanZob09aRVBQSURsOUdieFlnbVYzci1INHBXcjhaWWNVbFhxeGR3T2YtVjZfbmlWSjZnd3hJMThpVjFCUDRCN3pjMGdaXzhWb1J0c3o5WlNwRjRM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm BioCapital reports 10.4M-share stake in Erasca (NASDAQ: ERAS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbF9uN1hCQURSaGo0WGY0bzF3TE00aEJTLVZIMTd6aXZ4dVlUcTc4R2FWRnZsLVAwcUNlZVM3V2tVVVpoVTRkWXpleHNUNzhmVDBFSHJyTXZsenVneWNrZGUyV0RtdUNEVXpDV0lqX0ZLZFg5UGZwdVlwZ1RkOWZyUEJ5MTBodi1SbTRJTUJvanJxMDNneFhLbFQ3WXpsNVYwbmpDUU8zQXNEcjhFMV9wSkFfSkFaZ0RRM1Z3ckFfR3UxZTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Erasca teams up with Merck to test ERAS-0015 with Keytruda, shares jump (MRK:NYSE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxORG1FR3dZTVFWemlMWUI3OUtXd1NySk1Nd0VOaEUyY3pjYm9KRjVheXFWYWhWR2s2dm5NdUZWaDVNLXFjU2FxaExEQTBxd0xwNWs1OTROMXh6b2k2dzFfdF8zd2RwX0h1VFZWcjVtaVFydmx1ZEtHOGhqVU9SVXJYSlZBNG01TUNod1NMTUVHTFIzMmdMUXVJQ3M3WDY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSVNCYk85MmFqODVZTFBxQ242OGJVX2VPTXptSEZ0SFBjQktjOFhmeFlCQ3RHMGFWV1pUN3VGa01yVDFDdFJoV2I0dzRCZzU2c3hJRnNhNWkxN21uYnpsX09ZN2o4dmhtcWN1LVgzUUViZENIUnFNOV9aSEpiNmYxMlVWX1FVX1NvQmFUMkZYaVg5TUZIem9GSFpGZTZ4RElq?oc=5", "source_name": "Market source", "published_at": "2026-07-16T03:24:00+00:00", "published_display": "16 Jul 2026 03:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxPOHFIakhUVWt6Wl9WYUVhMDk2MnFIS0xnbUdIWXE2aEZYOEVob3ZzeVAweVVXYjRsWG1vRmlGYS16bzJQNkFSczZibW5uVU1WOTN0UUtSb19EbGthaTZFVHlUYU1SVUZ5TkdnR0JoSm9zNUtOTG9BRHJDRnBYWjdjQUtQR1BJcmV5dmlhcTkxM0tZaURqQjZHNDkxUzM5SzNCdjF1Um10MS1DaWxwN05iNWpnSHVsdHJkczVmWGU2cFdaQ2RPM013bVBEWkRrei1ZSUhiRm9aY05nVWEyN084cUlScEpPbUNtNmlKZ2F2WGptaDNpUnk1SDVFOUhvZmlpSjM0bmNJb0NiMzUtS2daNnMtdG5JZHdfLXBCck9ScTYyTnVNaHlVcFkxSDhRSzdzU0tmdzVHWm5GNkZoSm1SYnZB?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-16T00:00:00+00:00", "published_display": "16 Jul 2026 00:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Closes $632.5 Million Upsized Common Stock Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQNWVaUjdfc3Fjak5pZ0YzOXczVFhPQ3VfWVZST3pyVW1SZVUyV2JIaDBOdlliNzM0T1dwdTNCQ0IxLWdVbm9qVG1iSGhFQm1JOHF3V2pOZnBQTzZrRERKVVNvQ0Z1RmdYRl9scW1uNDU3bjhmZkVvYUthaHNuLVpsUzhVRkk4Q2Y1UHFQRk52aFRMRVhjemd0ZHpfTHNzZzNZWGFERFRhV2Zyam51RldZ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:29:17+00:00", "published_display": "15 Jul 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Erasca (ERAS) and Tenet Healthcare (THC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPcWdvLW1sT1B1cE9HQXpYOWUtZ3BUdFVNWW5aQm9lNGk2cHZSV2dLNzNQZmV4bnBObDZYR0UyTVV2OUNGQlNQeTJySXBlbnZ1Um5jMGp4TkJLZnhZZW81QXl1SmVJVDZoWkVfMjZXRWRzWlhpaU5aQ2w1ZmdKUnoxNkNXWGtMVnI0Wjk3SXlPTFFyVGloenlhdC12Vng2Ri12RUNsWGRfSS00R0RVTktNck1vTndqeE95ZFBuaUlJc0REcTkyR0Zndm55cGtFdUh6MUJObDhhUW9MLWowMS1IbmtERXJPaHpSbDlWV2RSRW9mYkozOGRfbQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-15T20:18:59+00:00", "published_display": "15 Jul 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-announces-closing-upsized-public-200100924.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:01:00+00:00", "published_display": "15 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca intends to use offering proceeds for oncology drug research", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOTFNZM3hXcTdKdkYxSGhvbUdRbUU3R0RfQ3RQbXFEbS1seWthUHJNRVM4SGlwblJVWVRxVXdUaUpjWGNhejJRX2cxZDNhZU1LVzA4OXZhbm52TUdjQTV2cGVOZm1WLTMwZmNIWF9NS0lvQ3l6MlY1cDZuUmRzdFNVdTJmU1hmNzA2cndPTmV2RG05YUJzT2tFWUlxcVRLalpTVWRlRGw5Sy1jWUpaYmROS1ZmSVBNWlVMWWNFSmpHaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:01:00+00:00", "published_display": "15 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca closes $632.5 million public stock offering", "summary": "Erasca Inc. (NASDAQ:ERAS), a precision oncology company, announced the closure of its public offering, raising approximately $632.5 million from the sale of over 36 million common shares at $17.50 each. The proceeds will fund research and development for its product candidates an", "url": "https://www.investing.com/news/company-news/erasca-closes-6325-million-public-stock-offering-93CH-4794147", "source_name": "Investing.com", "published_at": "2026-07-15T20:40:09", "published_display": "15 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "Erasca has announced the closing of its upsized public offering of 33,350,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $100.1 million before deduc", "url": "https://www.moomoo.com/news/post/73028785/press-release-erasca-announces-closing-of-upsized-public-offering-of", "source_name": "Moomoo", "published_at": "2026-07-15T19:40:09", "published_display": "15 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNNjRDQVRQSjNQNHVJb3lWTjlPeGoyeUZ4b3JzZjlVaG9GYjQ4UXE1eEJNdEprRHFsRml1X3QtSnFVUEM4R1NDcGZpUkFKODJHdHlSRkZ2SHRoY0NELUw3aU5nd1I0OVhjUi1zRXRWOEo0TTIyMjFRUDgyZEJsOFdFMUZBTWc0WHpUSkRnYnJTLUgxWUM1?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:13:39+00:00", "published_display": "15 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/erasca-eras-6-2-advancing-141017080.html", "source_name": "Simply Wall St.", "published_at": "2026-07-15T14:10:17+00:00", "published_display": "15 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxOdUhUWXpCdTlvTDZrdktRRVVMaUVpaFZuSXNkTkZ5SWRXNHd6OFFKckZSYUpvMTlxb1RZUGNPbm80aGlOQ19ub0FFXzRPYnVlOTFTaUR6bHVhbUZxTlI0azkwSXdBQlk2OWllc1BjU3FwZnJqczRPZkwwa1J5T19zYnQ4MTRlUUFvZThhNllJQ0RiYW52UzdyR3I1NmF0Tm0tZmxNSTF5OUJEVG5WbGxkRUR3dHdoRE5SUUlmS0gyOTVkako4b3pYRHRwLWRnX0xucnc5MlhQSEowb1lfMmI3ZHgwMjBvV3BoNzVMZUViRTdKRGl2LU9qU1M1M1oyaTU2RHlR?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-15T14:07:00+00:00", "published_display": "15 Jul 2026 14:07", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T09:02:37+00:00", "published_display": "15 Jul 2026 09:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Stock 12\u2011Month Price Target Raised to $21.09, Implies 18% Upside", "summary": "Analysts have raised the 12-month average price target for Erasca, Inc. (ERAS) stock to $21.45, up from $21.27, suggesting a 20% potential upside from its July 13 closing price. The consensus rating among 11 analysts remains \"Buy,\" with 9 analysts recommending a Buy and 2 recomme", "url": "https://www.tradingview.com/news/tradingview:230e96ff1f765:0-erasca-inc-stock-12-month-price-target-raised-to-21-09-implies-18-upside/", "source_name": "TradingView", "published_at": "2026-07-15T04:40:09", "published_display": "15 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit", "summary": "Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Erasca, Inc. (ERAS) for investors who suffered losses. The lawsuit alleges that Erasca failed to disclose that its preclinical data for ERAS-0015 was based on improper comparisons and ", "url": "https://www.morningstar.com/news/pr-newswire/20260714la03805/erasca-inc-eras-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit", "source_name": "Morningstar", "published_at": "2026-07-15T04:40:09", "published_display": "15 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Erasca Inc For: 14 July By Investing.com", "summary": "This article announces the filing of Form 424B5 by Erasca Inc. on July 14, as reported by Investing.com. It is a brief, straightforward notification of a regulatory filing, providing no further details within the article text itself beyond the company name and date of the filing.", "url": "https://ca.investing.com/news/stock-market-news/form-424b5-erasca-inc-for-14-july-93CH-4733976", "source_name": "Investing.com Canada", "published_at": "2026-07-15T04:15:35", "published_display": "15 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock sale", "summary": "Erasca Inc. (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, aiming to raise approximately $550.0 million in gross proceeds. The company plans to use the net proceeds, along with existing cash, to fund research and", "url": "https://www.stocktitan.net/sec-filings/ERAS/8-k-erasca-inc-reports-material-event-74cb25cf1a57.html", "source_name": "Stock Titan", "published_at": "2026-07-15T04:15:35", "published_display": "15 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Notice of August 10, 2026 Application Deadline", "summary": "Kahn Swick & Foti, LLC (KSF) has notified investors of Erasca, Inc. (NasdaqGS: ERAS) about a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product, specifically concerning improp", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327432/6713/en/Erasca-Inc-Notice-of-August-10-2026-Application-Deadline-for-Class-Action-Lawsuit-Contact-Lewis-Kahn-Esq-at-Kahn-Swick-Foti-LLC-Before-Application-Deadline.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T02:15:35", "published_display": "15 Jul 2026 02:15", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results", "summary": "Erasca (ERAS) shares surged 8.9% following encouraging Phase 1 clinical trial results for its cancer treatment candidate, ERAS-0015, which showed significant tumor shrinkage in pancreatic cancer patients. Investment firm Jefferies raised its price target for Erasca to $24 and rei", "url": "https://sg.finance.yahoo.com/news/erasca-eras-surges-8-9-234045926.html", "source_name": "Market source", "published_at": "2026-07-15T01:15:35", "published_display": "15 Jul 2026 01:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Erasca (ERAS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1URDRaa2pMb3VVNnpWWVFGMHl5Q1JtODF5bzN4eHd6RWFVZWJFNGQ5aGc1Z1NGellYSEw0bERYU3B5ckFrRndGcDhxa3VLZ1Z5ZF9KaUQxZVh4bEVRay03TGxHTk9MUVhYU1hBMks2MjZ6NUVtdV9aT0l6M28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T18:36:00+00:00", "published_display": "14 Jul 2026 18:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Erasca Stock Trading Higher Today? - Erasca (NASDAQ:ERAS)", "summary": "Erasca shares are trading higher today after the company unveiled updated preclinical data for its cancer candidate ERAS-0015, showing encouraging early activity. The company also priced an upsized public offering generating approximately $550 million to fund its pipeline and ope", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60454003/erasca-unveils-updated-cancer-candidate-progress-maps-path-toward-pivotal-cancer-trials", "source_name": "Benzinga", "published_at": "2026-07-14T18:15:35", "published_display": "14 Jul 2026 18:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS", "summary": "The Gross Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about a pending class action lawsuit with a lead plaintiff deadline of August 10, 2026. The lawsuit alleges that Erasca issued false and misleading statements regarding its ERAS-0015 drug, specifically conce", "url": "https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-erasca-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-10-2026---eras-302824963.html", "source_name": "PR Newswire", "published_at": "2026-07-14T14:10:54", "published_display": "14 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca investors face August 10 deadline in $11.59 per share securities fraud suit", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVEo3UkFJcVhINjEwRmVRc1ZwSmVYTVVoR2JFYkpCQV9VblZDallDOWk2ZzA5T0VST1VXZ2tEQnZTUWpNNDl4YlBKSGZrZ3ZndWpXX1FhNklwbFFQcTVHRlQ5VjVpa3g2UXBra05XWlUzYXZPejhqX29jVE56c2xZNl9GNEd5QkZVTy1CVEEtQVVCVW5kNnZSVVBubzl4cjh6QnlaWkVva090bFpsR3RoSA?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-14T12:27:28+00:00", "published_display": "14 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Prices Upsized Public Offering of $550 Million", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-prices-upsized-public-offering-082932571.html", "source_name": "MT Newswires", "published_at": "2026-07-14T08:29:32+00:00", "published_display": "14 Jul 2026 08:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Offering All Shares to Be Sold >ERAS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQLTNkWUFGVDExR0gxNGRXcU9IenluelB4OXhqR2NjTEtxTnk1VWxXTEFIQl92a0xLR3FvUlhBZXVxa1hHYWNOc1ZNR1lFOG1JSG5MdjNwVlg4THBaZUEzbkJfZFFPMTNNTWM3ZDBXTjVfVWotZ1NJVy1Gdl9PVE1ZQmpfb0NWOFhsRVpaMEhGSDl6a05TQ1J6NHFtWnVkVlI3aEV4akVKNy15UlpyY2ZkY0xzZkdRemZRYTZN?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T03:50:25+00:00", "published_display": "14 Jul 2026 03:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Erasca Announces Pricing of Upsized Public Offering of Common Stock", "summary": "Erasca has announced the pricing of an upsized public offering of its common stock. The offering is expected to generate significant interest from investors. This move could provide Erasca with additional capital to fund its operations and strategic initiatives.", "url": "https://www.moomoo.com/news/post/72896465/press-release-erasca-announces-pricing-of-upsized-public-offering-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T04:15:35", "published_display": "14 Jul 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Pricing of Upsized Public Offering of Common Stock", "summary": "Erasca, Inc. (Nasdaq: ERAS) has announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, expecting gross proceeds of approximately $550.0 million. The clinical-stage oncology company plans to use these proceeds, along with ", "url": "https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/erasca-announces-pricing-of-upsized-public-offering-of-common-stock/2383768", "source_name": "The Manila Times", "published_at": "2026-07-14T03:28:27", "published_display": "14 Jul 2026 03:28", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Plans to Use $550M Offering Proceeds for Drug Development", "summary": "Erasca (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share, expecting to raise approximately $550 million in gross proceeds. The company plans to use these funds, alongside existing cash, to finance research and developmen", "url": "https://www.stocktitan.net/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-dgwsm22haxu4.html", "source_name": "Stock Titan", "published_at": "2026-07-14T03:12:27", "published_display": "14 Jul 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (NASDAQ: ERAS) targets $500M stock sale to fund pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWTM5Rm5Hc3VPaFhYRkk2eTlWdzFJTXlkeEF0S0c2ck5YZV9jZEVGeXZubmFTNldJQU1saGNJaG4zTVZMRWVNNmt5QUtLTUNia3h1ZEN3RHA5ZkZna2FjMGlfdmt6RkhVMG5QdW1qSXZ5ekFyWjBrcGFTd3RkWG9YUGNiQ29idGVCV3paU092WDVGTVUxd1JvMEpsUUpqYVlPN3dZX3dnZ01yNmNNaWV5OUE2Q1BjVE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T21:24:10+00:00", "published_display": "13 Jul 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Plans $500 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-plans-500-million-underwritten-211745953.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:17:45+00:00", "published_display": "13 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Proposed $500 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbHFsNEE1T1RvRjc2cWowcmQ0UkhGcDhZM1BPd2wyQWp5dlNRNlhZamhkemtsTUNVbEhhaDNsT2FWdW1GS3J6aV9YQnBsREVEbXZ6Z3dqdE9fdi16OEsxUzU5VEg3Y09yRmlaU0h2Q2lBb2J5eGFGY05lcUtDSFhGTU5Ea3RpcmVSYUsySWRwVDd6aC1ldGMwWWlONkxOUWp2V1VIaFBZTlc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T20:30:00+00:00", "published_display": "13 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Announces Proposed Public Offering of $500 Million of Common Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/erasca-announces-proposed-public-offering-201900047.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T20:19:00+00:00", "published_display": "13 Jul 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug developer Erasca plans $500M stock sale, plus $75M option", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQeXhheXpiNkFlaVAzVW5MMUFtTUIxWEdfcHN3YVRsQks3cjNDeVYxd3dPUzl2RXpWYVZuX2d1djRnUVI4ZnMxdUEyRDNwMHMzZDdFZE9ZTFNmMWI5ZGlyR1Y0NkpMeXZhZmF5YkRkelpRcTdkbGhhRzV6SUNqVzFBNGpfd044Umt4YlVfdzVZaE5RaS1uYzVmTmdRM2QwdXAzQWN1MHZWRFVNUllOem04TE5qWHhFTF93VnlxdnlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:19:00+00:00", "published_display": "13 Jul 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca reports phase 1 data for RAS inhibitor ERAS-0015", "summary": "Erasca Inc. announced updated preliminary Phase 1 data for its investigational oral pan-RAS molecular glue, ERAS-0015, showing a 57% unconfirmed overall response rate in patients with RAS-mutant solid tumors, specifically KRAS G12X pancreatic ductal adenocarcinoma. The company pl", "url": "https://www.investing.com/news/company-news/erasca-reports-phase-1-data-for-ras-inhibitor-eras0015-93CH-4789151", "source_name": "Investing.com", "published_at": "2026-07-13T21:12:27", "published_display": "13 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. (NASDAQ: ERAS) sets up shelf to issue stock, debt and warrants", "summary": "Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, has filed an automatic shelf registration as a well-known seasoned issuer. This registration allows Erasca to offer various securities, including common stock, preferred stock, debt securities, and warrants", "url": "https://www.stocktitan.net/sec-filings/ERAS/s-3asr-erasca-inc-sec-filing-9f093d2d13ba.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:12:27", "published_display": "13 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit", "summary": "The Rosen Law Firm reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, of the August 10, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges Erasca and its executives made false and misleading ", "url": "https://www.keybiscayneportal.com/online_features/press_releases/eras-investors-have-opportunity-to-lead-erasca-inc-securities-fraud-lawsuit/article_bb42ef90-2f28-584d-a3e2-7332404979b3.html", "source_name": "Key Biscayne Portal", "published_at": "2026-07-13T16:10:55", "published_display": "13 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS", "summary": "Levi & Korsinsky, LLP is encouraging investors in Erasca, Inc. (NASDAQ: ERAS) who suffered losses to contact their firm regarding a pending class action lawsuit. Investors who purchased ERAS securities between January 14, 2025, and April 26, 2026, may be eligible to recover damag", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326285/3080/en/Levi-Korsinsky-Reminds-Erasca-Inc-Investors-of-the-Pending-Class-Action-Lawsuit-With-a-Lead-Plaintiff-Deadline-of-August-10-2026-ERAS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T13:41:24", "published_display": "13 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Erasca stock coverage as early-stage biotech By Investing.com", "summary": "Goldman Sachs has initiated coverage on Erasca Inc. (NASDAQ: ERAS) with an Early-Stage Biotech rating. Despite a significant surge in stock price over the past year, InvestingPro data suggests the company is overvalued. Erasca focuses on precision oncology, developing treatments ", "url": "https://m.in.investing.com/news/stock-market-news/goldman-sachs-initiates-erasca-stock-coverage-as-earlystage-biotech-93CH-5492649?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-13T09:41:24", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc.", "summary": "The Rosen Law Firm is encouraging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to secure legal counsel before the August 10, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges ", "url": "https://www.globenewswire.com/news-release/2026/07/12/3325869/673/en/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-Erasca-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ERAS.html", "source_name": "GlobeNewswire", "published_at": "2026-07-12T21:40:03", "published_display": "12 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) and its officers. The lawsuit seeks to recover damages for investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, alleging that the compa", "url": "https://natlawreview.com/press-releases/eras-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-erasca-9", "source_name": "The National Law Review", "published_at": "2026-07-12T12:11:04", "published_display": "12 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026", "summary": "Faruqi & Faruqi, LLP has reminded Erasca (NASDAQ: ERAS) investors of the upcoming August 10, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Erasca made false or misleading statements regarding its ERAS-0015 drug", "url": "https://natlawreview.com/press-releases/eras-shareholder-notice-faruqi-faruqi-llp-reminds-erasca-eras-investors", "source_name": "The National Law Review", "published_at": "2026-07-11T17:10:28", "published_display": "11 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS", "summary": "ClaimsFiler is reminding investors of Erasca, Inc. (NasdaqGS: ERAS) who suffered losses exceeding $100,000 to file lead plaintiff applications by August 10, 2026. This securities class action lawsuit alleges that Erasca and its executives made false and misleading statements rega", "url": "https://www.prnewswire.com/news-releases/erasca-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-erasca---eras-302823057.html", "source_name": "PR Newswire", "published_at": "2026-07-11T02:00:23", "published_display": "11 Jul 2026 02:00", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.", "summary": "Robbins LLP is reminding stockholders about a class action lawsuit filed against Erasca, Inc. (NASDAQ: ERAS) for alleged non-disclosure of patent and trade secret infringement risks related to its drug candidate ERAS-0015. The lawsuit covers investors who purchased securities bet", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325728/0/en/robbins-llp-urges-eras-stockholders-to-contact-the-firm-for-information-about-the-class-action-against-erasca-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T19:09:05", "published_display": "10 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Erasca\u2019s Shift Into Russell Growth Indexes (ERAS) Quietly Redefine Its Biotech Investment Story?", "summary": "In June 2026, Erasca, Inc. transitioned from Russell value and microcap benchmarks to Russell growth indexes, including the Russell 2000 and 3000 Growth series. This reclassification reshapes how institutions categorize the biotech company, which currently has no revenue, signifi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/does-erascas-shift-into-russell-growth-indexes-eras-quietly/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T17:40:22", "published_display": "10 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall ...", "summary": "The Schall Law Firm has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, covering investors who purchased shares between January 14, 2025, and April 26, 2026. The lawsuit claims Erasca made false and misleading statements regardin", "url": "https://www.caledonianrecord.com/eras-investors-have-opportunity-to-lead-erasca-inc-securities-fraud-lawsuit-with-the-schall/article_4e4b75f7-134e-564a-9aad-b46cab2ff31d.html", "source_name": "Caledonian Record", "published_at": "2026-07-10T15:09:05", "published_display": "10 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm", "summary": "The Gross Law Firm has issued a shareholder alert for Erasca, Inc. (NASDAQ: ERAS) investors who purchased shares between January 14, 2025, and April 26, 2026. This alert concerns a securities class action lawsuit alleging that Erasca made materially false and/or misleading statem", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325528/0/en/eras-shareholder-alert-erasca-inc-securities-class-action-lawsuit-investors-should-contact-the-gross-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T12:40:15", "published_display": "10 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca (ERAS) Pricey On Its Lawsuit And ERAS 0015 Risks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOVlwczZDeHh6UTZsOWdoLXBjaFVNUzdRVWgwbHo4U01iVmRHMy04MXQ0UGRLVndOVVVIZ2RZbmFyMlNXekdCVUsxZFA2bXNYRlZ4eW55cU5qTEY1MmRTOWJYVVEzd19GRmRfV0FaczFabjF4YzNPS2FaUF91LUhZQm5CekZsVFFhMmY1UzctclczRWZYNmhmY2dESzlseTVqWXVzU09sRW5wNFJuX0Jvc05oS2xncVdoTEJMZkNsR2JTbUdUa3Rja01hbml2dnZ2UUHSAdcBQVVfeXFMUHd2c3JZNjQxTnNHV1NlemQ0RldoMlVGc1p0UHBxelQtdXlHOXVyUDU4MndqeWhMWUFuaDh4cWJEeWEzRDROR0I4YzhRNDhGeHVVTF9VTjFmVmxCY0FRWHZaaUZ6eE1CLVVIVy14a24zRTBfeEFoNnNFSWpYakZzM19pX2VBWlByaTU0dkdINmcxaklZaVU2Mjc3WEZrNUc3SnpnNmc1Z0IwSmhRaFBLNS1FblNOc1ltM0RRRURjWDlScFVaM3hULUlpWjdPLXFKd25BR3VmNEU?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T18:42:48+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxORXhtQWFXZ3dNRnNKRnRJUVRIZG84VWxxSHE5VG9qNjBmVUZsS0lBYS0yT0JERHdlcU9rZXR1STJJUkhqMFNCQ0xVWUxmdWMtcEtEcEJTdGloN1NOMFFfRWJST2tqTnRuUEZjQjdXS0RHY1ZzYTVXNjRmMktvMDlFdjUtM05vY1lmVVFPMXpFTW1JTXRDdm1fdjNpMmdiM3I1azlDSUNaX3FpZHZZUV9WOWpWRm5OZTZGVlM5TlhPZmlaZ2ZIRFlURXB5bWxvYlcwTU9FLUN5ZlZOZ2ROTXZ5dVRWT2dPTWFSb2JTMjJNWlpzcVhnQVEzanFLclRPTmNiR3NENll5MlQxbHdkazlhdHFHOVdJOFpmeWJGMGtoaGhlZlNkQUN4VFI2ekVBNDkwUjNMNnBqY2g2X2xFWHQybXhrWHl6YUpFTXM3elYtN0V6Z1pJaVNZZTVmbjhUblE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-02T21:48:00+00:00", "published_display": "02 Jul 2026 21:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Erasca\u2019s (ERAS) Shift Into Russell Growth Indexes Reframing Its Core Investment Story?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (NASDAQ: ERAS) investors back board slate and KPMG auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMTlRZi11RU5IcE9tbUpXdWhLSTZVcnc1bTVJei14Mi00Y0RVdWdTWU5LZ1lkUHRPenY3cU53dXJPSFBCdHVHQlh6NWoxUy1DaFBuY09RUnAzYU9UTDA0M0ZoYjZ3R1NPdDJIXzRSeVJ2UFpHRU9Pd3EwaW11OEtSZU9qTUtNYUVvRUo0aWZSSkt6bHVEVWV1LWl1SUdvSVhk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOekNzaHYta3lvQ2ZJT0tVcDBXXzNqTmJoNnVWVHlKdEZZSm5Tdlk3RFhnaHM0MkRiZThNMDBnSkU0bG5QSWRSNUJjUFNUMzlyLVdiWWlIQ25WOFppUnhXQ2JKLWZjel8xc05Kd3RwcjJnMlZFUjh0dWRodmR5Q0ZkMklrRkx1dTRHbk44YXQ2UFhtTzA?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca (NASDAQ: ERAS) foundation reports three 8,333\u2011share sales in Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOVU40OUg0c0huNy1OZ0ZmTTRITXJnOWFNbmFmSjdncExHZTV1a0dhS0xEZ1U1aUY2U2RCYmxYUm1wZjJOVjM0MllhdHFMNldzYkp5LVkwM3pva0VfcktjUEx4LXJ0VDJ0SzdvZ29FSG5pdjRwcmxEbXpEcmh5S3YzeTZ0MVdheDdtZGxXdmR1Rkc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RTW Funds, Roderick Wong report 5.2% stake in Erasca (ERAS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ2Y0YTVxMTd4ZWRZM09Oc0x6cmxzcWJXcGRKRnZPM3hUak1vOXA0NVA3by1kZFExb2lldy12aXZTdmwyRzVldFM3VXdaRnk5YUFvUVhuTXk3RGhVbTRFZEdqYWhxanZob09aRVBQSURsOUdieFlnbVYzci1INHBXcjhaWWNVbFhxeGR3T2YtVjZfbmlWSjZnd3hJMThpVjFCUDRCN3pjMGdaXzhWb1J0c3o5WlNwRjRM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm BioCapital reports 10.4M-share stake in Erasca (NASDAQ: ERAS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbF9uN1hCQURSaGo0WGY0bzF3TE00aEJTLVZIMTd6aXZ4dVlUcTc4R2FWRnZsLVAwcUNlZVM3V2tVVVpoVTRkWXpleHNUNzhmVDBFSHJyTXZsenVneWNrZGUyV0RtdUNEVXpDV0lqX0ZLZFg5UGZwdVlwZ1RkOWZyUEJ5MTBodi1SbTRJTUJvanJxMDNneFhLbFQ3WXpsNVYwbmpDUU8zQXNEcjhFMV9wSkFfSkFaZ0RRM1Z3ckFfR3UxZTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Erasca teams up with Merck to test ERAS-0015 with Keytruda, shares jump (MRK:NYSE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxORG1FR3dZTVFWemlMWUI3OUtXd1NySk1Nd0VOaEUyY3pjYm9KRjVheXFWYWhWR2s2dm5NdUZWaDVNLXFjU2FxaExEQTBxd0xwNWs1OTROMXh6b2k2dzFfdF8zd2RwX0h1VFZWcjVtaVFydmx1ZEtHOGhqVU9SVXJYSlZBNG01TUNod1NMTUVHTFIzMmdMUXVJQ3M3WDY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 66, "sentiment_summary": {"positive": 11, "negative": 16, "neutral": 39, "score": 46, "total": 66, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 10.8, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 11, "negative_events": 16}, "market_context": {"has_market_context": true, "latest_close": 18.53, "latest_week": "2026-07-10", "one_week_move": 0.3, "four_week_move": 31.9, "twelve_week_move": -2.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.277452, "market_dynamics_buy_signal": false, "relative_strength": 99.379822, "fair_value_gap": 343.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 62.5164, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.3% over one week, +31.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 7}, {"label": "simplywall.st", "count": 6}, {"label": "PR Newswire", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 58}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Regulatory and legal", "count": 19}, {"label": "Earnings", "count": 10}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "58", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.3% over one week, +31.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns"}], "updated_at": "2026-07-16T08:10:37.029499+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}